Story perspectives

Chai Discovery Secures $130M Funding to Transform Drug Development

12/16/2025

Summary

Story summary

Chai Discovery, a San Francisco-based AI drug developer, announced a $130 million Series B funding round that values the company at $1.3 billion.
The round was co-led by Oak HC/FT and General Catalyst, with participation from OpenAI, Thrive Capital, and others.
Chai Discovery aims to revolutionize drug development with its latest model, Chai 2, which designs novel antibodies.
Josh Meier, the CEO of Chai Discovery, said AI can accelerate drug discovery and that the industry is on the brink of significant advancements.
Total funding for Chai Discovery now exceeds $225 million, following a $70 million Series A in August.

1 of 1

Story summary

Chai Discovery, a San Francisco-based AI drug developer, announced a $130 million Series B funding round that values the company at $1.3 billion.
The round was co-led by Oak HC/FT and General Catalyst, with participation from OpenAI, Thrive Capital, and others.
Chai Discovery aims to revolutionize drug development with its latest model, Chai 2, which designs novel antibodies.
Josh Meier, the CEO of Chai Discovery, said AI can accelerate drug discovery and that the industry is on the brink of significant advancements.
Total funding for Chai Discovery now exceeds $225 million, following a $70 million Series A in August.